Dynamic Technology Lab Private Ltd Has $1.13 Million Stock Holdings in 10x Genomics $TXG

Dynamic Technology Lab Private Ltd increased its position in shares of 10x Genomics (NASDAQ:TXG) by 146.7% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 96,279 shares of the company’s stock after acquiring an additional 57,256 shares during the quarter. Dynamic Technology Lab Private Ltd owned about 0.08% of 10x Genomics worth $1,126,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of TXG. Foundations Investment Advisors LLC acquired a new position in shares of 10x Genomics in the 3rd quarter valued at $665,000. Jump Financial LLC raised its stake in 10x Genomics by 130.2% during the 2nd quarter. Jump Financial LLC now owns 1,041,051 shares of the company’s stock worth $12,055,000 after buying an additional 588,769 shares during the period. AlphaQuest LLC raised its stake in 10x Genomics by 234.3% during the 3rd quarter. AlphaQuest LLC now owns 133,419 shares of the company’s stock worth $1,560,000 after buying an additional 93,514 shares during the period. Friedenthal Financial bought a new position in 10x Genomics during the third quarter worth about $924,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new position in 10x Genomics during the third quarter worth about $1,179,000. Institutional investors and hedge funds own 84.68% of the company’s stock.

Insider Activity at 10x Genomics

In other news, insider Benjamin J. Hindson sold 7,826 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $18.58, for a total transaction of $145,407.08. Following the completion of the transaction, the insider directly owned 424,779 shares of the company’s stock, valued at $7,892,393.82. This trade represents a 1.81% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Serge Saxonov sold 9,632 shares of 10x Genomics stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $18.58, for a total transaction of $178,962.56. Following the completion of the sale, the chief executive officer owned 1,061,924 shares in the company, valued at $19,730,547.92. This trade represents a 0.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 26,426 shares of company stock valued at $490,995. 9.39% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on TXG shares. Deutsche Bank Aktiengesellschaft set a $17.00 price target on 10x Genomics and gave the stock a “hold” rating in a report on Friday, February 13th. Morgan Stanley reiterated an “equal weight” rating and set a $20.00 price objective (up from $17.00) on shares of 10x Genomics in a report on Monday, December 1st. Weiss Ratings reiterated a “sell (e+)” rating on shares of 10x Genomics in a research report on Monday, December 22nd. Stifel Nicolaus raised their target price on shares of 10x Genomics from $20.00 to $25.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Finally, Piper Sandler lifted their price target on shares of 10x Genomics from $15.00 to $19.00 and gave the company a “neutral” rating in a research note on Tuesday, November 11th. Four equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $18.46.

10x Genomics Price Performance

TXG opened at $20.81 on Monday. The business’s 50-day moving average price is $19.88 and its two-hundred day moving average price is $16.40. 10x Genomics has a 1 year low of $6.78 and a 1 year high of $23.56. The company has a market capitalization of $2.66 billion, a price-to-earnings ratio of -59.46 and a beta of 2.20.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings results on Thursday, February 12th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.06. The company had revenue of $166.03 million for the quarter, compared to analyst estimates of $160.35 million. 10x Genomics had a negative return on equity of 6.89% and a negative net margin of 6.77%.The company’s quarterly revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.40) earnings per share. Sell-side analysts anticipate that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

About 10x Genomics

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.